Recursion Pharmaceuticals Inc (RXRX)
4.645
+0.68
(+17.00%)
USD |
NASDAQ |
Apr 09, 16:00
4.72
+0.08
(+1.61%)
After-Hours: 19:36
Recursion Pharmaceuticals Enterprise Value: 1.029B for April 8, 2025
View 4,000+ Financial Data Types:
Add
Browse
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Absci Corp | 180.61M |
| Corcept Therapeutics Inc | 7.054B |
| Catalyst Pharmaceuticals Inc | 2.081B |
| Enanta Pharmaceuticals Inc | -121.55M |
| Apellis Pharmaceuticals Inc | 2.389B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -178.91M |
| Revenue (Quarterly) | 4.511M |
| Total Expenses (Quarterly) | 188.28M |
| EPS Diluted (Quarterly) | -0.53 |
| Gross Profit Margin (Quarterly) | -183.6% |
| Profit Margin (Quarterly) | -3.97K% |
| Earnings Yield | -35.74% |
| Normalized Earnings Yield | -35.74 |